Rosuvastatin

How to order Rosuvastatin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Rosuvastatin on Prescriptsy

Rosuvastatin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Rosuvastatin is a potent HMG-CoA reductase inhibitor (statin) used to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events including heart attack and stroke.

It is one of the most effective statins currently available, capable of reducing LDL-C by up to 55% at the maximum dose.

Rosuvastatin is available as tablets in strengths of 5 mg, 10 mg, 20 mg, and 40 mg.

It is a prescription-only medicine (POM) in the United Kingdom, available as a generic or under the brand name Crestor (AstraZeneca).

Cardiovascular disease (CVD) remains the leading cause of death worldwide and the second most common cause of death in the United Kingdom, accounting for approximately 160,000 deaths per year.

Elevated LDL-cholesterol is one of the most important modifiable risk factors for atherosclerotic cardiovascular disease.

Statins are the cornerstone of cholesterol-lowering therapy and have been shown in numerous large-scale randomised trials to reduce cardiovascular morbidity and mortality.

The Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis demonstrated that for every 1 mmol/L reduction in LDL-C with statin therapy, the risk of major vascular events is reduced by approximately 22%.

This page provides a comprehensive clinical guide to rosuvastatin, covering how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about rosuvastatin

Before reading further, please note these essential safety points.

• Rosuvastatin must not be used during pregnancy or breastfeeding. Use effective contraception if you are of childbearing potential.
• Report unexplained muscle pain, tenderness, or weakness to your prescriber immediately, especially if accompanied by fever or malaise.
• The 40 mg dose has additional restrictions and is not appropriate for all patients.
• Rosuvastatin has fewer drug interactions than some other statins but still has important ones, including ciclosporin, gemfibrozil, and certain HIV medicines.
• Statins are associated with a small increased risk of type 2 diabetes, but the cardiovascular benefits outweigh this risk.

Understanding cholesterol and cardiovascular risk

Cholesterol is a waxy, fat-like substance that is essential for building cell membranes, producing hormones, and synthesising vitamin D. It is carried in the blood by lipoproteins.

LDL-cholesterol delivers cholesterol to tissues but, in excess, deposits cholesterol in arterial walls, initiating atherosclerosis.

HDL-cholesterol transports cholesterol from the arteries back to the liver for excretion, providing a protective effect.

Triglycerides are another type of blood fat that contribute to cardiovascular risk when elevated. The balance between these lipid fractions determines overall cardiovascular risk.

Atherosclerosis is the progressive accumulation of lipid-rich plaques in arterial walls.

Over time, these plaques can narrow the artery lumen, restricting blood flow, or rupture suddenly, triggering thrombosis that causes myocardial infarction (heart attack) or ischaemic stroke.

Lowering LDL-C with statins slows atherosclerotic progression, stabilises vulnerable plaques, reduces inflammation, and improves endothelial function, all of which contribute to reduced cardiovascular risk.

How rosuvastatin works

Rosuvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol biosynthesis.

By blocking this step in hepatocytes, rosuvastatin reduces intracellular cholesterol levels.

The liver responds by upregulating the expression of LDL receptors on the hepatocyte surface, which bind and internalise circulating LDL particles from the blood.

This receptor-mediated clearance is the primary mechanism by which statins lower blood LDL-cholesterol.

Rosuvastatin is the most potent statin in terms of LDL-C reduction per milligram dose.

It achieves approximately 45% LDL-C reduction at 10 mg daily and up to 55% at 40 mg daily.

In addition to LDL-C lowering, rosuvastatin reduces triglycerides by 10% to 35% and raises HDL-C by 5% to 15%.

Rosuvastatin is hydrophilic (water-soluble), which means it has greater hepatoselectivity than lipophilic statins (such as simvastatin and atorvastatin), potentially reducing the incidence of extrahepatic effects including muscle toxicity.

Unlike simvastatin and atorvastatin, which are extensively metabolised by cytochrome P450 3A4 (CYP3A4), rosuvastatin is minimally metabolised by cytochrome P450 enzymes (primarily CYP2C9).

This gives rosuvastatin a favourable drug interaction profile, as CYP3A4 inhibitors (macrolide antibiotics, azole antifungals, HIV protease inhibitors, grapefruit juice) do not significantly affect rosuvastatin levels.

However, rosuvastatin is a substrate of OATP1B1 and BCRP drug transporters, and medicines that inhibit these transporters (such as ciclosporin) can markedly increase rosuvastatin exposure.

Clinical evidence for rosuvastatin

The evidence base for rosuvastatin is extensive.

The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was a landmark randomised controlled trial of rosuvastatin 20 mg daily versus placebo in 17,802 apparently healthy individuals with elevated high-sensitivity C-reactive protein (hs-CRP) but normal LDL-cholesterol.

JUPITER demonstrated a 44% reduction in major cardiovascular events and a 20% reduction in all-cause mortality with rosuvastatin over a median follow-up of 1.9 years.

This trial expanded the evidence for statin therapy beyond traditional lipid-lowering indications.

The METEOR trial demonstrated that rosuvastatin 40 mg daily significantly slowed the progression of carotid intima-media thickness (a surrogate marker for atherosclerosis) compared with placebo in patients with subclinical atherosclerosis and relatively low cardiovascular risk.

The ASTEROID trial showed that rosuvastatin 40 mg daily achieved regression of coronary atherosclerosis as measured by intravascular ultrasound, demonstrating that aggressive LDL-C lowering can reverse established coronary disease.

Head-to-head comparisons with other statins have consistently shown that rosuvastatin achieves greater LDL-C reduction at equivalent or lower milligram doses.

The STELLAR trial compared rosuvastatin with atorvastatin, simvastatin, and pravastatin across multiple dose levels and confirmed rosuvastatin's superior potency for LDL-C reduction.

Rosuvastatin compared with other statins

Five statins are commonly prescribed in the UK: atorvastatin, rosuvastatin, simvastatin, pravastatin, and fluvastatin.

NICE Clinical Guideline CG181 (cardiovascular disease: risk assessment and reduction) recommends atorvastatin as the first-line statin for both primary and secondary prevention.

Rosuvastatin is typically used when atorvastatin is not tolerated or when greater LDL-C reduction is needed.

Rosuvastatin achieves approximately 5% to 10% greater LDL-C reduction than atorvastatin at comparable doses (for example, rosuvastatin 10 mg is roughly equivalent to atorvastatin 20 mg in LDL-C lowering).

The key advantage of rosuvastatin over simvastatin and atorvastatin is its minimal CYP3A4 metabolism, which reduces the risk of drug interactions.

Patients taking medicines that inhibit CYP3A4 (such as certain macrolide antibiotics, antifungals, or calcium channel blockers like verapamil and diltiazem) may be better suited to rosuvastatin.

However, rosuvastatin has its own interaction profile through OATP transporters, particularly with ciclosporin.

Simvastatin is the most commonly prescribed statin in the NHS (largely for historical reasons, as it was the first generic high-potency statin), but atorvastatin has increasingly replaced it due to greater potency, once-daily dosing flexibility, and fewer dose restrictions.

Pravastatin and fluvastatin are less potent and generally reserved for patients who cannot tolerate more potent statins.

Dosage and administration

Rosuvastatin can be taken at any time of day, with or without food. This flexibility is an advantage over simvastatin, which should be taken at bedtime.

The usual starting dose is 5 mg to 10 mg once daily. Dose should be titrated at intervals of at least 4 weeks.

The maximum dose is 40 mg daily, but this dose has additional prescribing restrictions and should only be used under specialist supervision for patients with severe hypercholesterolaemia who have not achieved their target with 20 mg.

Special dosing considerations apply to patients of Asian origin, patients with moderate renal impairment, and patients with risk factors for myopathy. See the detailed dosage section and warnings for specific guidance. Liver function tests should be checked before starting rosuvastatin.

Side effects of rosuvastatin

Muscle effects

Muscle symptoms are the most commonly discussed side effect of statins.

These range from mild myalgia (muscle aches without CK elevation) to rare myopathy (muscle symptoms with CK elevation above 10 times the upper limit of normal) and extremely rare rhabdomyolysis (severe muscle breakdown that can cause acute kidney injury).

The true incidence of statin-associated muscle symptoms in clinical practice is debated.

Randomised controlled trials report myalgia rates of approximately 5% to 10% in both statin and placebo groups, suggesting a significant nocebo effect.

However, real-world rates of reported muscle symptoms are higher.

If muscle symptoms develop, your prescriber may check CK levels, reduce the dose, try intermittent dosing (such as every other day), or switch to an alternative statin.

Liver effects

Elevated liver transaminases (ALT, AST) occur in a small percentage of patients, usually in a dose-dependent manner. These elevations are typically mild, transient, and asymptomatic.

Clinically significant liver injury with statins is extremely rare. Check liver function before starting treatment and if symptoms of hepatotoxicity develop.

Diabetes risk

Statins, including rosuvastatin, are associated with a small increased risk of new-onset type 2 diabetes.

This risk is approximately 1 additional case per 255 patients treated for 4 years with rosuvastatin, based on JUPITER trial data.

The risk is highest in patients with pre-existing risk factors for diabetes. The cardiovascular benefits of statin therapy substantially outweigh this risk.

The MHRA, EMA, and FDA have all concluded that statins remain appropriate for patients at cardiovascular risk despite the diabetes signal.

Other side effects

Headache, dizziness, constipation, nausea, and abdominal pain are common. Proteinuria may occur, particularly at higher doses, and is usually tubular and transient.

Insomnia, paraesthesia, and memory effects have been uncommonly reported and are generally reversible. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Active liver disease, pregnancy, breastfeeding, severe renal impairment (at doses above 20 mg), concomitant ciclosporin, and myopathy.

The 40 mg dose has additional contraindications including Asian ethnicity, moderate renal impairment, hypothyroidism, personal or family history of muscular disorders, and concomitant fibrate use.

Drug interactions

Ciclosporin is contraindicated (markedly increases exposure). Gemfibrozil should be avoided. Fibrates increase myopathy risk. Warfarin may require more frequent INR monitoring. Antacids reduce absorption.

HIV and hepatitis C protease inhibitors may require dose restrictions. Unlike simvastatin and atorvastatin, rosuvastatin is not significantly affected by CYP3A4 inhibitors or grapefruit juice.

Monitoring

Liver function tests before starting treatment. Lipid profile at baseline and after approximately 3 months to assess response. CK only if muscle symptoms develop. Annual cardiovascular risk review as part of ongoing clinical care.

How to get rosuvastatin in the UK

Rosuvastatin is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

NICE recommends atorvastatin as first-line; rosuvastatin is used when atorvastatin is not tolerated or when greater LDL-C reduction is required. Generic rosuvastatin is widely available.

Sources

• Rosuvastatin tablets, Summary of Product Characteristics (EMC)
• Rosuvastatin, British National Formulary (BNF)
• Cardiovascular disease: risk assessment and reduction, NICE CG181
• Statins, NHS
• MHRA Yellow Card Scheme